Back to Search Start Over

Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options

Authors :
Ross, Jeffrey S.
Badve, Sunil
Wang, Kai
Sheehan, Christine E.
Boguniewicz, Ann B.
Otto, Geoff A.
Yelensky, Roman
Lipson, Doron
Ali, Siraj
Morosini, Deborah
Chliemlecki, Juliann
Elvin, Julia A.
Miller, Vincent A.
Stephens, Philip J.
Source :
Archives of Pathology & Laboratory Medicine. May, 2015, Vol. 139 Issue 5, 642
Publication Year :
2015

Abstract

Context.--Metastatic metaplastic breast carcinoma (MPBC) is an uncommon, but aggressive, tumor resistant to conventional chemotherapy. Objective.--To learn whether next-generation sequencing could identify potential targets of therapy for patients with relapsed and metastatic MPBC. Design.--Hybridization capture of 3769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to a minimum of 50 ng of DNA extracted from 20 MPBC formalin-fixed, paraffinembedded specimens and sequenced to high uniform coverage. Results.--The 20 patients with MPBC had a median age of 62 years (range, 42-86 years). There were 9 squamous (45%), 9 chondroid (45%), and 2 spindle cell (10%) MPBCs, all of which were high grade. Ninety-three genomic alterations were identified, (range, 1-11) with 19 of the 20 cases (95%) harboring an alteration that could potentially lead to a targeted treatment option. The most common alterations were in TP53 (n = 69; 75%), PIK3CA (n = 37; 40%), MYC (n = 28; 30%), MLL2 (n = 28; 30%), PTEN (n = 23; 25%), CDKN2A/B (n = 19; 20%), CCND3 (n = 14; 15%), CCNE1 (n = 9; 10%), EGFR (n = 9; 10%), and KDM6A (n = 9; 10%); AKT3, CCND1, CCND2, CDK4, FBXW7, FGFR1, HRAS, NF1, PIK3R1, and SRC were each altered in a single case. All 16 MPBCs (100%) that were negative for ERBB2 (HER2) overexpression by immunohistochemistry and/or ERBB2 (HER2) amplification by fluorescence in situ hybridization were also uniformly (100%) negative for ERBB2 amplification by next-generation sequencing-based copy-number assessment. Conclusions.--Our results indicate that genomic profiling using next-generation sequencing can identify clinically meaningful alterations that have the potential to guide targeted treatment decisions in most patients with metastatic MPBC. (Arch Pathol Lab Med. 2015;139:642-649; doi: 10.5858/arpa.2014-0200-0A)<br />Metaplastic carcinoma of the breast (MPBC) is an uncommon, malignant tumor with a variable histologic appearance that differs substantially from classic invasive ductal adenocarcinoma and invasive lobular adenocarcinoma. (1-5) Metaplastic [...]

Details

Language :
English
ISSN :
15432165
Volume :
139
Issue :
5
Database :
Gale General OneFile
Journal :
Archives of Pathology & Laboratory Medicine
Publication Type :
Academic Journal
Accession number :
edsgcl.510937202
Full Text :
https://doi.org/10.5858/arpa.2014-0200-0A